Free shipping on all orders over $ 500

 About 33 results found for searched term "MEK inhibitor" (0.105 seconds)

Cat.No.  Name Target
M14169 GDC-0623 MEK
RG 7421; MEK inhibitor 1
GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM).
M14170 MEK inhibitor MEK
MEK inhibitor is a potent MEK inhibitor with antitumor potency.
M49714 MEK1 Derived Peptide Inhibitor 1 ERK
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor.
M49718 Myristoyl-MEK1 Derived Peptide Inhibitor 1 ERK
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1.
M1652 AS703026 MEK
MSC1936369B,Pimasertib
AS703026 is a novel selective MEK1/2 inhibitor, and induces pleiotropic anti-myeloma activity in vitro and in vivo.
M1661 AZD6244 MEK
Selumetinib, ARRY-142886
AZD6244 (ARRY-142886, Selumetinib) is a potent MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nM.
M1662 AZD8330 MEK
ARRY-424704, ARRY-704
AZD8330 (ARRY-424704) is a novel, selective, highly efficacious, uncompetitive MEK inhibitor with an IC50 of 7 nM.
M1744 ARRY-162 (Binimetinib) MEK
MEK-162; Binimetinib; ARRY-438162
ARRY-162 (MEK-162; Binimetinib) is a selective, potent inhibitor of MEK and cellular pERK with IC50 of 12 nM and 11 nM, respectively.
M1750 TAK-733 MEK
TAK-733 is a potent and selective MEK allosteric site inhibitor with IC50 of 3.2nM for the treatment of cancer.
M1759 GSK1120212 (Trametinib) MEK
JTP-74057, GSK212
Trametinib (GSK1120212; Jtp-74057) is an orally effective MEK inhibitor with IC50 of 2 nM against MEK1 and MEK2, respectively. Trametinib can activate autophagy and induce apoptosis.
M1763 Mirdametinib (PD0325901) MEK
Mirdametinib;PD325901
Mirdametinib (PD0325901) is a highly potent and selective MEK inhibitor with an IC50 in C26 cells of 0.33nM.
M1905 PD318088 MEK
PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor.
M1957 BMS-536924 IGF-1R
Bms-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50 of 100 nM and 73 nM, respectively. It also showed moderate inhibitory activity against Mek, Fak and Lck, but almost no inhibitory activity against Akt1 and MAPK1/2.
M2915 PD 198306 MEK
PD 198306 is a cell-permeable and highly selective MEK inhibitor with IC50 of 8 nM.
M3626 Cobimetinib (GDC-0973) MEK
Cobimetinib ; XL518
Cobimetinib (GDC-0973, RG7420) is an effective, selective, oral MEK1 inhibitor with an IC50 of 4.2 nM against MEK1. In addition, Cobimetinib is an inhibitor of Akt.
M5236 BI-847325 MEK
BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively.
M8046 PD-184161 Others
PD-184161 is a MEK inhibitor.
M9014 RO4987655 MEK
CH4987655
RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM.
M10369 RO5126766 (VS-6766) MEK
CH5126766; VS 6766; Avutometinib
RO5126766 (CH5126766, VS 6766) is a first-in-class dual MEK/RAF inhibitor with IC50 values of 8.2 nM, 19 nM, 56 nM and 160 nM for BRAF V600E, BRAF, CRAF and MEK1, respectively.
M10503 GW284543 (UNC10225170) MEK
UNC10225170
GW284543 (UNC10225170) is a selective MEK5 inhibitor, which reduces pERK5 and decreases endogenous MYC protein.
M11250 Zapnometinib MEK
PD0184264; ATR-002
Zapnometinib (PD0184264), an active metabolite of CI-1040, is an MEK inhibitor with an IC50 value of 5.7 nM. Zapnometinib has antiviral and antibacterial activity against influenza viruses.
M14168 Cobimetinib hemifumarate MEK
GDC-0973 hemifumarate; XL-518 hemifumarate
Cobimetinib hemifumarate is a novel selective MEK1 inhibitor, and the IC50 value against MEK1 is 4.2 nM. In addition, Cobimetinib is an inhibitor of Akt.
M14171 Selumetinib sulfate MEK
AZD6244 sulfate; ARRY-142886 sulfate
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
M14172 Trametinib (DMSO solvate) MEK
GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM.
M20028 WAY-114228 MEK
WAY-114228 is a MEK1 inhibitor.
M21071 MAP855 MEK
MAP855 is a potent, selective and orally effective ATP-competitive MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 inhibits wild-type and mutant MEK1/2 equally.
M21987 Cobimetinib racemate MEK
Cobimetinib racemate is the racemate of Cobimetinib, a potent, selective, orally available MEK1 inhibitor with an IC50 for MEK1 inhibition of 4.2 nM.In addition, Cobimetinib is an Akt inhibitor.
M27786 U0126  MEK
U0126 is a potent, non-ATP-competitive, selective inhibitor of MEK1 and MEK2 with IC50s of 72 nM and 58 nM, respectively.In addition, U0126 is an autophagy and mitophagy inhibitor and inhibits LPA-induced entosis.
M28882 EBI-1051  MEK
EBI-1051 is a highly potent and orally efficacious MEK inhibitor with an IC50 of 3.9 nM.
M29856 MEK-IN-4  MEK
MEK-IN-4 is a MEK inhibitor. MEK-IN-4 can be used for the research of inflammatory disorders and cancers.
M42142 GW284543 hydrochloride MEK
GW284543 (UNC10225170) hydrochloride is a selective MEK5 inhibitor.
M42145 MEK-IN-6 hydrate MEK
MEK-IN-6 hydrate is a MEK inhibitor.
M43554 MEK-IN-6 ERK
MEK-IN-6 is a MEK inhibitor.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.